Comparative Pharmacology
Head-to-head clinical analysis: EXDENSUR versus FOSAMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXDENSUR versus FOSAMAX.
EXDENSUR vs FOSAMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EXDENSUR (generic name not specified) is a novel oral anticoagulant that selectively inhibits activated factor XI (FXIa), thereby reducing thrombin generation and preventing clot formation without significantly affecting hemostasis.
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite in bone matrix and impairing osteoclast activity through inhibition of farnesyl pyrophosphate synthase.
5 mg orally twice daily
70 mg orally once weekly for osteoporosis; 10 mg orally once daily for Paget's disease.
None Documented
None Documented
Terminal elimination half-life is 8 hours in healthy adults, prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min).
Terminal elimination half-life is approximately 10.5 years in bone, reflecting slow release from the skeleton. Plasma half-life after intravenous administration is about 1 hour.
Primarily renal excretion of unchanged drug (85%) and minor biliary excretion (15%). Total clearance is 120 mL/min.
Renal excretion of unchanged drug is the primary route (approximately 50% of absorbed dose). Unabsorbed drug is eliminated in feces. No biliary excretion.
Category C
Category C
Bisphosphonate
Bisphosphonate